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Abstract 
Background: Exposure to a moderate to high dose of ionizing radiation (IR) not only causes acute radiation syn-
drome but also induces long-term (LT) bone marrow (BM) injury. The latter effect of IR is primarily attributed to the 
induction of hematopoietic stem cell (HSC) senescence. Granulocyte colony-stimulating factor (G-CSF) is the only 
treatment recommended to be given to radiation victims soon after IR. However, clinical studies have shown that 
G-CSF used to treat the leukopenia induced by radiotherapy or chemotherapy in patients can cause sustained low 
white blood cell counts in peripheral blood. It has been suggested that this adverse effect is caused by HSC and 
hematopoietic progenitor cell (HPC) proliferation and differentiation stimulated by G-CSF, which impairs HSC self-
renewal and may exhaust the BM capacity to exacerbate IR-induced LT-BM injury.
Methods: C57BL/6 mice were exposed to 4 Gy γ-rays of total body irradiation (TBI) at a dose-rate of 1.08 Gy per min-
ute, and the mice were treated with G-CSF (1 μg/each by ip) or vehicle at 2 and 6 h after TBI on the first day and then 
twice every day for 6 days. All mice were killed one month after TBI for analysis of peripheral blood cell counts, bone 
marrow cellularity and long-term HSC (CD34-lineage-sca1+c-kit+) frequency. The colony-forming unit-granulocyte 
and macrophage (CFU-GM) ability of HPC was measured by colony-forming cell (CFC) assay, and the HSC self-renewal 
capacity was analyzed by BM transplantation. The levels of ROS production, the expression of phospho-p38 mitogen-
activated protein kinase (p-p38) and p16INK4a (p16) mRNA in HSCs were measured by flow cytometry and RT-PCR, 
respectively.
Results: The results of our studies show that G-CSF administration mitigated TBI-induced decreases in WBC and the 
suppression of HPC function (CFU-GM) (p < 0.05), whereas G-CSF exacerbated the suppression of long-term HSC 
engraftment after transplantation one month after TBI (p < 0.05); The increase in HSC damage was associated with 
increased ROS production, activation of p38 mitogen-activated protein kinase (p38), induction of senescence in HSCs.
Conclusion: Our findings suggest that although G-CSF administration can reduce ARS, it can also exacerbate TBI-
induced LT-BM injury in part by promoting HSC senescence via the ROS-p38-p16 pathway.
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Background
The hematopoietic system is exceedingly sensitive to ion-
izing radiation (IR). Acute radiation syndromes (ARSs) 
such as infection, bleeding, anemia and other clinical 
manifestations are mainly because of acute bone marrow 
(BM) suppression induced by IR. BM suppression is a life-
threatening hazard when exposure to a moderate to high 
dose of total body irradiation (TBI) [1, 2]. The hemat-
opoietic progenitor cells (HPCs) and a small amount 
of hematopoietic stem cells (HSCs) undergo apoptosis 
after exposure to IR, thus resulting in acute BM suppres-
sion within days [3]. Its clinical manifestations could be 
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successfully managed by the use of hematopoietic growth 
factors (HGFs) [4]. However, even though some irradiated 
patients recover from IR-induced acute myelosuppres-
sion, they may develop long-term BM injury manifested 
by decreasing the HSC reserves and damaging HSC self-
renewal ability subsequently. Unlike acute bone mar-
row suppression, residual BM damage is larvaceous, and 
under homeostatic conditions, patients with residual BM 
damage usually have a prolonged period of normal blood 
cell counts despite decreasing in HSC reserves. However, 
the clinical manifestation of residual BM injury has been 
largely overlooked because of this latency. Moreover, the 
risk of residual BM damage has been failed to consider by 
the seemingly normal blood cell counts and BM cellular-
ity, especially after HGFs treatment.
Granulocyte colony-stimulating factor (G-CSF) is an 
important member of the hematopoietic cytokine fam-
ily secreted by immune and non-immune cells that can 
not only stimulate the proliferation and differentiation of 
hematopoietic cells [5] but also regulate the immune [6], 
nervous [7], and endocrine systems [8]; it also plays a major 
role as a regulator of hematopoiesis and innate immune 
responses [9, 10]. Stimulating the patient’s own marrow 
recovery through the use of G-CSF is therefore a potentially 
effective countermeasure in certain irradiated patients.
G-CSF can stimulate HPC proliferation and differen-
tiation to reduce acute hematopoietic radiation injury 
[11, 12]. G-CSF  can  reduce  the  incidence  of  neutro-
penia  associated  with  radiation-  and  chemotherapy-
induced  marrow  aplasia [13–15],  what’s  more,  G-CSF 
activate  neutrophils  to  enhance  it’s  function,  such  as 
promoting  microbiocidal  activity,  which  is impor-
tant  for  the  host’s  nonspecific  immune  response  medi-
ated  by  opportunistic  infection [16, 17], and pegylated 
G-CSF (a longer half-life of G-CSF) has been reported 
to mitigate neutropenia, anemia, and thrombocytope-
nia in irradiated B6D2F1/J mice [18].  However, G-CSF 
treatment after chemotherapy may directly or indirectly 
promote hematopoietic stem cell (HSC) proliferation 
and differentiation, leading to HSC exhaustion [19, 20]; 
G-CSF used to treat the leukopenia induced by radiother-
apy or chemotherapy in patients can cause sustained low 
white blood cells in peripheral blood. However, whether 
G-CSF accelerates HSC exhaustion after TBI and the 
associated mechanisms have yet to be elucidated [21]. 
The effects of G-CSF were therefore investigated using a 
sublethal dose TBI mouse model.
Results
G‑CSF ameliorates ionizing radiation‑induced reduction 
in peripheral blood cells
Previous studies have showed that exposure to sub-lethal 
doses of total body γ-irradiation (TBI) not only leaded 
to acute BM injury but also resulted in long-term bone 
marrow (LT-BM) suppression [22–24]. To investigate 
how G-CSF treatment effects on IR-induced hemopoietic 
system injury, the numbers of peripheral blood cells and 
bone marrow mononuclear cells (BMMNCs) were ana-
lyzed 1 month after 4 Gy TBI. Mice irradiated with 4 Gy 
γ-rays received injections of rhG-CSF or saline accord-
ing to the schedules indicated in Fig. 1a. Peripheral blood 
was obtained via the orbital sinus 1 month after 4 Gy TBI, 
and WBCs, platelets, and hematocrit were measured as 
described previously [25]. As shown in Fig. 1b, the num-
ber of WBCs in vehicle-treated mice showed an obvious 
reduction 1 month after 4 Gy TBI compared with the con-
trol mice, but there was no difference in number of RBCs, 
HBG, and PLT between control and TBI mice. G-CSF 
treatment alone had no effect on peripheral blood counts 
compared with control mice, whereas G-CSF administra-
tion attenuated the reduction in the number of WBCs in 
4 Gy TBI group, and it almost recovered the number of 
WBCs after exposure to 4 Gy TBI. However, there was no 
significant difference in the number of BMMNCs among 
all groups (two separate studies), as shown in Fig. 1c, sug-
gesting that bone marrow cells recovered to normal levels 
1 month after 4 Gy TBI. This finding indicates that G-CSF 
can relieve IR-induced acute BM injury effectively.
G‑CSF did not affect the phenotype in hematopoietic cells 
dramatically
IR could reduce the number and frequency of HSPCs 
(hematopoietic stem and progenitor cells), and acceler-
ate the HSC exhaustion. Our results show that BMNCs 
returned to normal levels 1  month after TBI (Fig.  1c). 
To investigate the effect of G-CSF on the frequency 
and numbers of LSK (lin-scal  +  ckit+), ST-HSCs 
(CD34 + lin-scal + ckit+) and LT-HSCs (CD34-lineage-
scal + ckit+) after exposure to 4 Gy TBI, we analyzed the 
frequencies and numbers of different hematopoietic cell 
populations in BM cells by flow cytometry, as shown in 
Fig. 2a. The results of this assay revealed that there were 
no significant differences in the frequencies or numbers 
of LSK, ST-HSCs and LT-HSCs between irradiated and 
control mice 1  month after TBI (Fig.  2b, c, d). Further 
analysis revealed that G-CSF administration after 4  Gy 
TBI did not significantly change the frequencies or num-
bers of LSK, ST-HSCs, and LT-HSCs in BM cells (Fig. 2b, 
c, d). This result suggests that G-CSF did not affect the 
phenotype in different populations of hematopoietic cells 
one month after 4 GyTBI.
G‑CSF mitigated TBI‑induced suppression of HPC function
In addition, we performed a CFC assay to examine 
whether hematopoietic cells from irradiated mice main-
tained their clonogenic function after G-CSF treatment, 
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as illustrated in Fig.  3. As expected, radiation exposure 
significantly reduced the production of colony form-
ing units-granulocyte–macrophage (CFU-GM) 1  month 
after 4  Gy TBI by 43.6  %. Whereas mice that received 
G-CSF treatment after exposure to 4  Gy TBI increased 
the production of CFU-GM dramatically, G-CSF treat-
ment mice did not show a significant difference com-
pared with the control mice. These results suggest that 
G-CSF could attenuate the radiation-induced suppres-
sion of hematopoietic progenitor cells.
Effect of G‑CSF on TBI‑induced LT‑BM injury
A previous study showed that G-CSF exacerbated 
hematopoietic stem cell injury caused by repeated 
administration of cytotoxic agents [20]. To investigate 
whether G-CSF treatment reinforced HSC long-term 
injury induced by IR, competitive repopulation assays 
were performed. We used the whole bone marrow 
from Ly5.1 mice after receiving vehicle or G-CSF treat-
ment according to the schedule illustrated in Fig.  1a as 
donor cells. Donor cells with the competitive cells from 
Ly5.2 mice bone marrow were injected together into 
the Ly5.2 recipients in a 4:1 ratio. The donor derived T, 
B -lymphocytic and myeloid lineage engraftments in the 
peripheral blood cells of recipient mice were measured 
8 and 16 weeks after 1st transplantation (Fig. 4c, d), and 
16 weeks after 2nd transplantation (Fig. 4e).
As expected, the untreated donor cells remained stable 
engraftment. However, the HSCs from vehicle treated 
mice after expose to 4  Gy TBI dramatically decreased 
the long-term and multilineage engraftment by approxi-
mately forty percent after first transplantation compared 
with that from control mice (Fig.  4b). These findings 
indicate that mice exposure to a sublethal dose of TBI 
(4.0  Gy) could cause long-term BM injury. Our results 
show that G-CSF treatment after exposure to 4  Gy TBI 
would exacerbate the LT-HSC injury compared with 
4 Gy irradiated mice, which is manifestated by a further 
decreased donor-derived leukocytes, T cells, B cells, and 
myeloid cells engraftment in peripheral blood at 8 weeks 
and 16  weeks after the first transplantation (Fig.  4d). 
Intriguingly, G-CSF treatment alone 1  month later led 
to a decrease in the engraftment of donor-derived cells 
16 weeks after first transplantation.
a b
c
Fig. 1 G-CSF treatment schedule. a Mice were divided into four groups randomly and treated daily with i.p. vehicle or G-CSF (1 µg/time, twice a 
day) for 7 days after exposure to 4 Gy TBI and then fed sterilely for 1 month after TBI. Sham-irradiated mice were treated in the same way regarded as 
a control. b The numbers of white blood cells (WBCs), red blood cells (RBCs), Hgb and platelets (PLTs) in peripheral blood were quantified after the 
mice were killed 1 month later. c Bone marrow nucleated (BMN) cells were quantified 1 month after various treatments. The data are presented as 
mean ± SEM, six mice/group. **p < 0.005 (vs. control); ##p < 0.005 (vs. 4 Gy)
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To assess the self-renewal capacity of HSCs, secondary 
bone marrow transplantations were performed. Donor 
derived multilineage engraftment was maintained from 
the vehicle-treated and G-CSF-treated mice in second-
ary recipients, 4  Gy irradiated donor mice bone mar-
row cells showed a marked decreased engraftment, and 
G-CSF treated mice after exposure to 4  Gy TBI would 
further exacerbate the injury, donor-derived leukocytes, 
T cells, B cells, and myeloid cells in the peripheral blood 
showed a further decreased engraftment 16  weeks after 
second transplantation (Fig.  4e). Thus, G-CSF further 
reduced the repopulating and self-renewal capacity of 
HSCs induced by IR.
G‑CSF promoted TBI‑induced increases in ROS production 
in HSCs
TBI could cause long-term BM suppression by induc-
ing chronic oxidative stress and senescence in HSCs [26, 
27]. Previous study showed that exposure to a sublethal 





Fig. 2 The effect of G-CSF on the frequency and number of long-term HSCs 1 month after TBI. Mice received vehicle or G-CSF treatment twice a 
day for 7 days after exposure to 0 or 4 Gy TBI as illustrated in Fig. 1a. The BM cells were collected after the mice were killed 1 month after various 
treatments and analyzed for long-term HSCs and short-term HSCs by flow cytometry. a Arepresentative gating strategy of LT-HSC and ST-HSC 
was analyzed by flow cytometry; b The frequencies of the LT-HSCs (CD34 + lineage-scal + ckit + cells) and the numbers of LT-HSCs pre mouse; c 
The frequencies of the ST-HSCs (CD34 + lineage-scal + ckit + cells) and the numbers of ST-HSCs pre mouse; d The frequencies of HSCs (lineage-
scal + ckit + cells) and the numbers of HSCs per mouse. The data are presented as mean ± SEM, six mice/group
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selectively [28]. In our study, the production of ROS was 
dramatically increased in HSCs rather than in HPCs 
from vehicle-treated mice after exposure to 4  Gy TBI, 
as shown in Fig.  5b, indicating that persistent oxidative 
stress existed in HSCs 1  month after TBI. Intriguingly, 
G-CSF administration after exposure to 4 Gy TBI led to 
a much higher level of ROS in HSCs than that in the 4 Gy 
TBI group and G-CSF group. These findings suggest that 
G-CSF further exacerbates the chronic oxidative stress in 
HSCs induced by IR, thus deteriorating TBI-caused long-
term BM suppression.
G‑CSF promotes TBI‑induced increase in p38 expression 
and senescence in HSCs
Ionizing radiation leads to the suppression of HSC func-
tion, partly through the induction of oxidative stress in 
HSCs, and p38 is of great importance to regulate the HSC 
self-renewal, and it can be activated by ROS. In addi-
tion, p38 involves in mediating radiation-induced HSC 
senescence, which is an element attributable to long-
term bone marrow injury [29]. In our experiment, G-CSF 
exacerbated the HSC injury induced by IR, characterized 
by decreased repopulation and self-renewal functions. To 
determine whether G-CSF compromised HSC function 
by activating the ROS-p38-p16 pathway to promote the 
induction of HSC senescence, we measured the intracel-
lular p38 phosphorylation (p-p38) and the p16 mRNA 
expression, which have been used as biomarkers of HSC 
senescence.As shown in Fig.  6b, 4Gy TBI resulted in a 
dramatic increase in p38 activation in HSCs (lineage-
scal + ckit+ cells). G-CSF treatment alone also resulted 
in a high-level of expression of p-p38. G-CSF admin-
istration induced a much higher level of p-p38 in HSCs 
1  month after TBI compared with that in TBI group. 
Moreover, our results showed that exposure to radiation 
significantly increased the expression of p16 mRNA in 
HSCs and G-CSF administration potentiated the induc-
tion (Fig. 6c). These results suggest that G-CSF promoted 
radiation-induced senescence in bone marrow hemat-
opoietic cells, in part via the ROS-p38-p16 pathway.
Discussion
G-CSF mobilizes HSCs to peripheral blood and 
increases peripheral leukocyte counts; thus, G-CSF 
is widely used in the treatment of myelosuppression 
induced by radiotherapy and chemotherapy. However, 
it has been shown in experimental models that, G-CSF 
administration may have some adverse effects on 
hematopoietic stem cells after receiving multiple doses 
of cytotoxic agents treatments, which themselves could 
induce the primitive stem cells injury [20]. Ronald 
et al. also reported that G-CSF impeded bone marrow 
cells recovery from damage caused by cytotoxic agents 
through increasing differentiation at the expense of self-
renewal [19]. Schuettpelz et  al. reported that Toll-like 
receptor (TLR) expression and signaling after G-CSF 
treatment resulted in phenotypic HSCs expansion but 
reduced their repopulation and self-renewal ability 
[30]. However, whether G-CSF exacerbates IR-induced 
HSC function and the mechanisms have yet to be elu-
cidated. In our study, we found that TBI decreased 
WBC counts in PB and CFU-GM and induced persis-
tent oxidative stress, intracellular phospho-p38 expres-
sion and senescence in HSCs. Treatment with G-CSF 
effectively inhibited TBI-induced reduction of WBC 
and HSC clonogenic function defects. Our experiments 
also showed that G-CSF could damage long-term HSC 
repopulating and self-renewal ability, which could fur-
ther compromise long-term HSC function after IR. 
In our study, G-CSF administration could exacerbate 
TBI-induced long-term repopulation activity defects by 
further increasing ROS production and p38. A previ-
ous study showed that G-CSF combined with the p38 
inhibitor SB203580 could efficiently increase the clo-
nogenic function of BM hematopoietic progenitor cells 
(HPCs) and the frequency of HSCs, ST-HSCs and LT-
HSCs 30 days after TBI, What’s more, the combination 
of G-CSF and SB203580 could increased the cobble-
stone area-forming cell (CAFC) of HSCs of irradiated 
mice [22, 31], which is an important indicator of HSC 
function, suggesting that G-CSF treatment may dam-
age HSC function in part by inducing ROS-p38 oxida-
tive signal expression. HSC senescence is an important 
factor contributing to long-term bone marrow suppres-
sion, TBI could induce HSC senescence, we found that 
G-CSF treatment after TBI would further aggravating 
Fig. 3 G-CSF administration reduced TBI-induced suppression of HPC 
proliferation. Mice received vehicle or G-CSF treatment twice a day for 
7 days after exposure to 0 or 4 Gy TBI as illustrated in Fig. 1a. BMMNCs 
were harvest from the sacrificed mice 1 month after various treat-
ments and cultured in MethoCult GF M3534 methylcellulose medium 
for 7 days, and then analyzed the colony-forming unit-granulocytes 
and macrophages (CFU-GM). The data are presented as mean ± SEM, 
six mice/group. **p < 0.005 vs. control; ##p < 0.005 (vs. 4 Gy)




Fig. 4 G-CSF exacerbated the HSCs long-term and multilineage engraftment reduction induced by TBI. a Competitive transplantation assay were 
performed by transplanting a 4:1 ratio of 45.1 donor cells to 45.2 competitive cells into 9.5 Gy-irradiated recipients. After stable hematopoietic 
reconstitution (16 weeks), mice were sacrificed, and bone marrow cells were harvested and transplanted into secondary recipients in the same 
way as the first competitive assay. A peripheral blood chimera for total cells, T cells, and B cells was assessed after 16 weeks. b Representative 
flow cytomerty plots showing donor-derived cell engraftment in peripheral blood cells. Right: percentage of donor (CD45.1+) cell engraftment. 
Left: engraftment of donor-derived T cells (CD45.1 + CD3 + cells), B cells (CD45.1 + B220 + cells), and myeloid cells (CD45.1 + CD11 + and/or 
Gr-1 + granulocyte–monocyte–macrophage) in the peripheral blood. c Donor -derived bone marrow cells multilineage engraftments were deter-
mined at 8 weeks in lethally irradiated recipients after first transplantation. d Donor -derived bone marrow cells multilineage engraftments ten-
dency were measured at 8 and 16 weeks in lethally irradiated recipients after first transplantation. e Donor -derived bone marrow cells multilineage 
engraftments were determined at 16 weeks in lethally irradiated recipients after second transplantation of BM-MNCs from mice receiving various 
treatments described in Fig. 1a. Results are presented as mean ± SE. * p < 0.05, ** p < 0.005 vs. control; # p < 0.05, ## p < 0.005 (vs. 4 Gy) (N = 9–12 
recipient mice/group)
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HSC senescence, which was indicated by further 
increased p16 mRNA expression.
Wang et al. previously reported the p38 pathway plays 
an important role in mediating hematopoietic stem cell 
senescence induced by IR, and it can be activated by oxi-
dative stress, and pharmacological inhibition of p38 can 
effectively abate IR-induced residual BM injury [32, 33]. 
The authors observed that p38 was selectively activated 
in irradiated hematopoietic cells, and the long-term BM 
cell culture assay revealed that the activation of p38 was 
sustained for up to 5  weeks after IR. Inhibition of p38 
activity with a specific inhibitor, such as SB203580, abated 
IR-induced suppression of BM hematopoietic cell func-
tion along with a significant reduction in p16 expression 
and SA-b-gal activity. These findings and our results dem-
onstrated that the activation of p38 by oxidative stress 
can serve as a prominent mediator to induce the LT-HSC 
bone marrow suppression. G-CSF plays an important role 
in activating p38 expression and HSC senescence.
In addition, G-CSF signaling results in the suppres-
sion of osteoblast lineage cells in monocytic cells, and 
the osteoblast lineage cells play an important role in 
maintaining HSPCs in the bone marrow [34]. Singh 
et  al.  demonstrated that neutrophil expansion, a physi-
ological consequence response to G-CSF, could lead to 
the apoptosis in osteolineage cell populations of BM and 
reduce the production of HSC retention factors such 
as SDF-1, SCF, and VCAM-1, so it can disrupt the BM 
niche, and lead to HSPC mobilization [15]. G-CSF pro-
motes HSC mobilization, likely affects the niche sign-
aling, then reduces HSC maintaining in stroma, and 
exacerbates the exhaustion of the HSC pool; however, 
such assumptions still require further experimental 
validation.
Previous studies have not reported on how G-CSF 
administration affects the number and function of long-
term hematopoietic stem cells after TBI. For the first time, 
our results show that G-CSF would not affect the number 
a
b c
Fig. 5 G-CSF treatment deteriorates the TBI-induced increase in ROS production in HSCs. Mice received vehicle or G-CSF treatment twice a day for 
7 days after exposure to 0 or 4 Gy TBI as illustrated in Fig. 1a. BM-MNCs were harvested from scarified mice 1 month after exposure to TBI. The ROS 
production in HPCs and HSCs were analyzed. a Flow cytometric analysis was used to to estimate the ROS production in HPCs and HSCs. b The levels 
of intracellular ROS fold expression in HPCs are presented as the mean ± SE of DCF MFI. c The levels of intracellular ROS fold expression in HSCs are 
presented as the mean ± SE of DCF MFI
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of LSK cells and HSCs but would further reduce the func-
tion of long-term hematopoietic stem cells 1 month after 
exposure to TBI, elevate the level of ROS, and induce the 
expression of p38; the results also suggest that G-CSF 
further impedes hematopoiesis in bone marrow injured 
by IR partly by increasing ROS-p38 oxidative signaling 
and HSC senescence. Our experiments also show that 
G-CSF administered alone compromised HSCs’ repopu-
lating ability, particularly B cell engraftment after the first 
transplantation due to increased P38 activity, which is 
not regulated by ROS. Based on previous studies, G-CSF 
can regulate HSC function by toll-like receptor signaling 
[35, 36], and p38 is an important downstream activating 
protein of toll-like receptor signaling [37]. Therefore, we 
suggest that G-CSF treatment alone compromises HSC 
function through inflammatory signals.
Singh et  al. reported that Genistein, which is used 
as an antineoplastic and antitumor agent, can be 
combined with G-CSF to protect HSCs against G-CSF-
induced DNA damage [38]. Li et al. also reported that 
G-CSF in combination with p38 inhibitors can increase 
CAFC of the HSCs injured by ionizing radiation. We 
expect that a combination of such drugs with G-CSF 
can effectively mobilize HSCs, reducing the clinical 
symptoms of acute radiation injury and decreasing the 
likelihood of further long-term bone marrow suppres-
sion. Our results show that G-CSF can decrease HSC 
function by exacerbating the ROS-p38 oxidative stress 
pathway and HSC senescence, suggesting that this anti-
oxidant and anti-senesence agent could be a promising 
choice for combination. In conclusion, our hematopoi-
etic stem cell experiments provide a new perspective 
on the application of radiotherapy and treatment of 
acute radiation sickness, with the aim of reducing the 




Fig. 6 G-CSF treatment increased TBI-induced p38 expression and senescence in HSCs. Mice received vehicle or G-CSF treatment twice a day for 
7 days after exposure to 0 or 4 Gy TBI as illustrated in Fig. 1a. The BM cells were collected after the mice were killed 1 month after receiving various 
treatments, and then p38 activation in HSCs (lineage-ckit + scal +, LKS +) was analyzed by flow cytometry. a Representative flow cytometric 
analysis of phosphorylated p38 (p38) in HSC cells, b the percentages of p-p38 positive cells under various treatment conditions are presented as 
mean ± SE (n = 5), c the levels of p16mRNA expression in sorted HSCs were analyzed by RT-PCR and are expressed as mean ± SE of fold changes 
compared to control (n = 3)
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Methods
Mice
Male C57BL/6-Ly-5.1 (Ly5.1) mice were purchased from 
the Institute of Laboratory Animal Sciences (PUMC, 
Beijing, China); C57BL/6  J (Ly5.2) mice were purchased 
from Vital River (Beijing, China).All the mice housed 
in the certified animal facility of the Institute of Radia-
tion Medicine of the Chinese Academy of Medical Sci-
ences (CAMS). Mice were 8–12 weeks of age, weighting 
20–25 g. The Animal Use Committee at the Institute of 
Radiation Medicine of CAMS (No 1403) approved all the 
experimental procedures used during the research.
TBI and G‑CSF administration
Twenty four male mice were divided into four groups 
randomly: (a) control group; (b) 4  Gy group; (c) 
G-CSF group; (d) G-CSF  +  4  Gy group. Mice from 
G-CSF  +  4  Gy group and 4  Gy group were exposure 
to 4  Gy γ-rays (dose rate:1.08  Gy per minute) using an 
Exposure Instrument Cammacell-40 (Atomic Energy of 
Canada Lim), and then administered with G-CSF or vehi-
cle (saline in 100 ul volume) twice a day for 7 days with 
intraperitoneal injections at an dose of 1  μg/mouse [25, 
39]. The mice from G-CSF group and control group were 
not exposure to irradiation, and were treated in a manner 
similar to that described above.
Peripheral blood cell and BM nucleated cell (BMNCs) 
counts
Mice were anesthetized, and then blood was obtained via 
the orbital sinus and was collected in anticoagulant tubes. 
The numbers of peripheral blood cells included white 
blood cells (WBCs), red blood cells, platelets, and the 
hemoglobin (HGB) were measured by an MEK-7222  K 
(Nihonkohden, Japan). BM cells were harvested as previ-
ously described [25]. The number of viable BMNCs was 
counted and expressed as ×107/femur.
Hematopoietic cells phenotypic analysis by flow cytometry
Briefly, 1  ×  106 hematopoietic cells harvested from 
mouse bone marrow were incubated with biotin-conju-
gated lineage antibodies (CD4, CD8, CD45R/B220, Gr-1, 
Mac-1 and Ter-119) and then stained with streptavidin-
Percp to separate the lineage-positive cells. The cells 
were washed with PBS and incubated with anti-CD16/
CD32 antibody to block Fc receptors. Finally, the fre-
quencies of HPCs (Lin–Sca1–c-kit1  +  cells), LSK cells 
(Lin–Sca1 +  c-kit +  cells), short-term HSCs (ST-HSCs, 
CD34  +  LSK cells), and long-term HSCs (LT-HSCs, 
CD34–LSK cells) were analyzed with a flow cytometer 
(BD Accuri C6, San Jose, CA). The data were analyzed 
using BD Accuri C6 software.
Colony‑forming cells (CFC) assay
The CFC assay was implemented by culturing BM cells 
in MethoCult GF M3534 methylcellulose medium (Stem-
Cell Technologies, BC, Canada), and the colony-forming 
unit-granulocyte macrophage (CFU-GM) with more 
than 30 cells were scored as a colony under an inverted 
microscope according to the manufacturer’s instructions. 
The results were expressed as the numbers of CFU-GM 
per 105 BMNCs.
Competitive repopulation assay (CAR)
Competitive repopulation assays were performed as 
described previously [26, 27]. Specifically, for first trans-
plantation, the cells (1 × 106 BMCs) were harvested from 
the donor Ly5.1 mice and then mixed with 2 × 105 com-
petitive BMCs from Ly5.2 mice. The mixed cells were 
transplanted into lethally irradiated (9.5  Gy TBI) Ly5.2 
recipient mice though lateral canthus vein injection. For 
second transplantation, CD45.2 cells (1  ×  106 BMCs) 
sorted from 1st transplantation recipient mice accom-
pany with 2  ×  105 competitive BMCs from Ly5.2 mice 
were transplanted into lethally irradiated (9.5 Gy) Ly5.2 s 
recipient mice. To analyze the donor cells engraftment, 
peripheral blood was harvested at 8 and 16  weeks after 
first transplantation and 16 weeks after second transplan-
tation. The red blood cells were lysed by 1 ×  RBC lysis 
(eBioscience Inc. San Diego, CA, USA), and the blood 
samples were stained with anti-CD45.1-FITC, anti-
CD45.2-PE, anti-CD3-APC, anti-B220-PerCP, and anti-
Gr-1 and CD11b-PE/Cy7 and were analyzed by BD FACS 
AriaIII.
Flow cytometric analysis of intracellular ROS
1  ×  106 BM lineage-negative hematopoietic cells were 
stained with anti-Sca-1–APC and anti-c-kit–PE-Cy7 
antibodies and then incubated with DCFDA (10 μM) for 
30 min at 37  °C. To evaluate the productions of ROS in 
HPCs and HSCs, the mean fluorescence intensity (MFI) 
of 2′, 7′-dichlorofluorescein (DCF) was measured by 
using a flow cytometer as described previously [26, 27].
Analysis of p38 activation by phosphor‑specific flow 
cytometry
Approximately 1  ×  106 freshly isolated BMNCs were 
first incubated with specific antibodies to separate the 
lineage negative cells (CD4, CD8, CD11b, CD45R/B220, 
Ter-119, and Gr-1- biotin-conjugated) and then stained 
with streptavidin-Percp, Sca-1-PE, and c-kit-APC. The 
cells were then fixed and permeabilized with BD Cytofix/
Cytoperm™ Fixation/Permeabilization Solution Kit (BD 
Pharmingen, San Diego, CA), and stained with FITC con-
jugated with anti-p-p38 antibody (BD Pharmingen,San 
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Diego, CA) (1:50) for one hour at 4  °C according to the 
manufacturers’ instructions. After washing with PBS, 
cells were analyzed on a flow cytometer, and the data 
were analyzed using BD Accuri C6 software (BD Accuri 
C6, San Jose, CA).
Isolation of HSCs (Lin– c‑kit+ Sca‑1+ cells)
These experiments were performed as we previously 
reported [28, 40].
Quantitative real‑time PCR
Total cellular RNA was extracted from about 20,000 
sorted HSCs using TRIzol reagent (Invitrogen, Carls-
bad, CA) following the manufacturer’s instructions. RNA 
yield and quality were determined by measuring absorb-
encies at 260 and 280  nm, respectively. First-strand 
cDNA was synthesized from total RNA by RevertAid 
First Stand cDNA Synthesis Kit (Thermo scientific) 
according to the manufacturer’s protocol. Quantitative 
real-time PCR was performed using TaqMan PCR prim-
ers and MasterMix (Applied Biosystems). Taqman MGB 
probes for the p16Ink4a (catalog number: Mm00494449_
m1), and- the housekeeping gene Gapdh (catalog num-
ber: Mm99999915_g1) were obtained from Applied 
Biosystems (Foster City, CA). All samples were analyzed 
in triplicate using an ABI Prism 7500 Sequence Detection 
System (Applied Biosystems). The threshold cycle (CT) 
values for each reaction were determined and averaged 
using TaqMan SDS analysis software (Applied Biosys-
tems). The changes in gene expression were calculated by 
the comparative CT method (fold changes = 2−△△CT) 
as described previously [41].
Statistical analysis
The differences between treated and control groups were 
examined by unpaired Student’s t tests. Differences were 
considered significant at p  <  0.05. All of these analyses 
were performed using GraphPad Prism from GraphPad 
Software (San Diego, CA, USA).
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